Creative Medical Technology Holdings (Nasdaq:CELZ) - Hisse Senedi Fiyatı, Haberler ve Analizler

CELZ Stoklara Genel Bakış

CELZ temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Kazançların yılda 72.73% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 4% oranında arttı

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $11K )

Anlamlı bir piyasa değeri yok ( $4M )

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Hissedarlar geçen yıl sulandırıldı

Creative Medical Technology Holdings, Inc. Rakipler

Oncternal Therapeutics

NasdaqCM:ONCT

US$3.4m

Organovo Holdings

NasdaqCM:ONVO

US$5.4m

BioCardia

NasdaqCM:BCDA

US$7.5m

Oragenics

NYSEAM:OGEN

US$3.3m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Creative Medical Technology Holdings
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$2.55
52 Haftanın En Yüksek Seviyesi	US$10.28
52 Haftanın En Düşük Seviyesi	US$2.41
Beta	5.03
11 Aylık Değişim	-27.29%
3 Aylık Değişim	-24.26%
1 Yıllık Değişim	-45.74%
33 Yıllık Değişim	-91.87%
5 Yıllık Değişim	-98.87%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	CELZ	US Biotechs	US Pazar
7D	-5.7%	2.4%	2.2%
1Y	-45.7%	16.2%	31.7%

Getiri vs. Endüstri: CELZ geçen yıl % 16.2 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: CELZ geçen yıl % 31.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is CELZ's price volatile compared to industry and market?
CELZ volatility
CELZ Average Weekly Movement	16.6%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: CELZ hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: CELZ 'nin haftalık oynaklığı ( 17% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	4	Tim Warbington	www.creativemedicaltechnology.com

Ticari aşamada bir biyoteknoloji şirketi olan Creative Medical Technology Holdings, Inc. Amerika Birleşik Devletleri'nde immünoterapi, endokrinoloji, üroloji, nöroloji ve ortopedi alanlarında yeni biyolojik terapötiklere odaklanmaktadır. Şirket, erektil disfonksiyonu tedavi etmek için CaverStem; genital hassasiyet ve kuruluk kaybının tedavisi için FemCelz; ve dejeneratif disk hastalığını tedavi etmek için rejeneratif bir kök hücre prosedürü olan StemSpine'ı sunmaktadır. Ayrıca, birden fazla hastalık için bir immünoterapi platformu olan ImmCelz; kadın kısırlığı tedavisi için OvaStem; Tip 1 diyabet tedavisi için CELZ-201; kronik bel ağrısı tedavisi için AlloStemSpine ve erken yumurtalık yetmezliğinin bir sonucu olarak kısırlığı tedavi etmek için Alova geliştirmektedir.

Creative Medical Technology Holdings, Inc. Temel Bilgiler Özeti

Creative Medical Technology Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CELZ temel i̇stati̇sti̇kler
Piyasa değeri	US$4.46m
Kazançlar(TTM)	-US$5.32m
Gelir(TTM)	US$11.00k

404.5x

P/S Oranı

-0.8x

F/K Oranı

CELZ aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CELZ gelir tablosu (TTM)
Gelir	US$11.00k
Gelir Maliyeti	US$4.40k
Brüt Kâr	US$6.60k
Diğer Giderler	US$5.32m
Kazançlar	-US$5.32m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-3.04
Brüt Marj	60.00%
Net Kâr Marjı	-48,345.28%
Borç/Özkaynak Oranı	0.2%

CELZ uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

CELZ Stoklara Genel Bakış

Ödüller

Risk Analizi

Creative Medical Technology Holdings, Inc. Rakipler

NasdaqCM:ONCT

US$3.4m

NasdaqCM:ONVO

US$5.4m

NasdaqCM:BCDA

US$7.5m

NYSEAM:OGEN

US$3.3m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

New minor risk - Shareholder dilution

Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million.

Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million.

New minor risk - Share price stability

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Recent updates

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

New minor risk - Shareholder dilution

Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million.

Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million.

New minor risk - Share price stability

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Creative Medical Technology Holdings, Inc., Annual General Meeting, Jul 19, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access

Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem

New major risk - Financial position

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 20, 2023

Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain

Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem™ (Celz-201-Ddt) for the Treatment of Chronic Lower Back Pain

Creative Medical Technology Holdings Regains Compliance with Nasdaq Listing Requirements

Creative Medical Technology Holdings, Inc. (NasdaqCM:CELZ) announces an Equity Buyback for $2 million worth of its shares.

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of Its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz(R) Immunotherapy Platform

Creative Medical Technology Holdings, Inc. Announces Next Milestone Achievements in ImmCelz Platform Development

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Creative Medical Technology Holdings, Inc. Announces Positive Three-Year Follow-Up Data for the Company's Stemspine Pilot Study

Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc. Announces Fda Clearance of Investigational New Drug (Ind) Application for Allostem(Tm), A Novel Cell Therapy for the Treatment of Type 1 Diabetes

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 19, 2022

Creative Medical Technology Holdings, Inc. Develops AlloStem Clinical Cell Line

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Creative Medical Technology Holdings Receives Non-Compliance Notice from Nasdaq

Creative Medical Technology Holdings, Inc. announced that it has received $17.000001 million in funding

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc. Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

High number of new and inexperienced directors

Creative Medical Technology Holdings Deleted from Other OTC

Less than half of directors are independent

Creative Medical Technology Holdings, Inc. announced that it has received $3.78775 million in funding

Creative Medical Technology Holdings, Inc. announced that it expects to receive $3.788 million in funding

Creative Medical Technology Holdings Identifies Synergy Between Immcelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes

Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease

FDA Responds to Creative Medical Technology Holdings, Inc. Regarding its ImmCelz® IND for Stroke Treatment

Creative Medical Technology Holdings, Inc. Announces Fda Acknowledgment of Ind Application for Immcelz® to Treat Stroke

Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using Stemspine® Personalized Adult Stem Cell Therapy

Creative Medical Technology Holdings Provides Update on ImmCelz® FDA Application

Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection Using ImmCelz®

Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented Ovastem® Female Infertility/Ovarian Failure Treatment

Creative Medical Technology Holdings, Inc. Announces the Recruitment of Dr. Caigan Du to the Scientific Advisory Board

Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of Immcelz® Therapeutic Activity

Creative Medical Technology Holdings Inc. Recruits Dr. Boris Reznik to the Scientific Advisory Board

Creative Medical Technology Holdings Inc. Files Investigational New Drug Application with FDA for Treatment of Stroke using ImmCelz® Regenerative Immunotherapy

Creative Medical Technology Holdings Announces Patent Filing Based on Preclinical Data in Model of Heart Attack Using ImmCelz Regenerative Immunotherapy

Creative Medical Technology Holdings Announces Successful Application of ImmCelz® Immunotherapy for Treatment of Stroke

Creative Medical Technology Holdings Files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular Immunotherapy

Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Creative Medical Technology Holdings, Inc. Temel Bilgiler Özeti